Who are tirofiban intracoronary bolus-only's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bivalirudin with and without eptifibatide, Abciximab + UFH, Glycoprotein IIb/IIIa inhibitors, Tirofiban+Oral Dual Antiplatelet Therapy, Intravenous tirofiban before endovascular thrombectomy, A-Phase: tirofiban; Z-Phase simvastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tirofiban-intracoronary-bolus-only.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

tirofiban intracoronary bolus-only — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

tirofiban intracoronary bolus-only (tirofiban intracoronary bolus-only) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: glycoprotein IIb/IIIa inhibitor. Area: Cardiovascular.

phase 3 glycoprotein IIb/IIIa inhibitor glycoprotein IIb/IIIa receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

tirofiban intracoronary bolus-only (tirofiban intracoronary bolus-only) — Kosuyolu Heart Hospital. Tirofiban is a non-peptide antagonist of the glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
tirofiban intracoronary bolus-only TARGET	tirofiban intracoronary bolus-only	Kosuyolu Heart Hospital	phase 3	glycoprotein IIb/IIIa inhibitor	glycoprotein IIb/IIIa receptor
Bivalirudin with and without eptifibatide	Bivalirudin with and without eptifibatide	LifeBridge Health	marketed	Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide)	Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor
Abciximab + UFH	Abciximab + UFH	Deutsches Herzzentrum Muenchen	marketed	Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant)	Platelet glycoprotein IIb/IIIa receptor
Glycoprotein IIb/IIIa inhibitors	Glycoprotein IIb/IIIa inhibitors	University of Luebeck	marketed	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
Tirofiban+Oral Dual Antiplatelet Therapy	Tirofiban+Oral Dual Antiplatelet Therapy	Second Affiliated Hospital of Soochow University	marketed	Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy	Glycoprotein IIb/IIIa receptor
Intravenous tirofiban before endovascular thrombectomy	Intravenous tirofiban before endovascular thrombectomy	General Hospital of Shenyang Military Region	phase 3	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
A-Phase: tirofiban; Z-Phase simvastatin	A-Phase: tirofiban; Z-Phase simvastatin	Organon and Co	phase 3	Antiplatelet agent + HMG-CoA reductase inhibitor (combination therapy)	Glycoprotein IIb/IIIa receptor (tirofiban); HMG-CoA reductase (simvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (glycoprotein IIb/IIIa inhibitor class)

Kosuyolu Heart Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tirofiban intracoronary bolus-only — Competitive Intelligence Brief. https://druglandscape.com/ci/tirofiban-intracoronary-bolus-only. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab